Hydrophilic Realgar Nanocrystals Prolong the Survival of Refractory Acute Myeloid Leukemia Mice Through Inducing Multi-Lineage Differentiation and Apoptosis

References

• Bose P, Konopleva MY. ORY-1001: overcoming the differentiation block in AML. Cancer Cell. 2018;33(3):342–343. doi:10.1016/j.ccell.2018.02.014
   PubMed Web of Science ®Google Scholar
• Dhall A, Zee BM, Yan F, Blanco MA. Intersection of epigenetic and metabolic regulation of histone modifications in acute myeloid leukemia. Front Oncol. 2019;9:432. doi:10.3389/fonc.2019.00432
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Cortes JE. Mutations in AML: prognostic and therapeutic implications. Hematology Am Soc Hematol Educ Program. 2016;2016(1):348–355. doi:10.1182/asheducation-2016.1.348
   PubMed Web of Science ®Google Scholar
• Sykes DB, Kfoury YS, Mercier FE, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell. 2016;167(1):171–186.e15. doi:10.1016/j.cell.2016.08.057
   PubMed Web of Science ®Google Scholar
• de The H. Differentiation therapy revisited. Nat Rev Cancer. 2018;18(2):117–127. doi:10.1038/nrc.2017.103
   PubMed Web of Science ®Google Scholar
• Sell S. Leukemia: stem cells, maturation arrest, and differentiation therapy. Stem Cell Rev. 2005;1(3):197–205. doi:10.1385/scr:1:3:
   PubMedGoogle Scholar
• Ma Y, Liu L, Jin J, Lou Y, Mills K. All-trans retinoic acid plus arsenic trioxide versus all-trans retinoic acid plus chemotherapy for newly diagnosed acute promyelocytic leukemia: a meta-analysis. PLoS One. 2016;11(7):e0158760. doi:10.1371/journal.pone.0158760
   PubMed Web of Science ®Google Scholar
• Cai SF, Levine RL. Genetic and epigenetic determinants of AML pathogenesis. Semin Hematol. 2019;56(2):84–89. doi:10.1053/j.seminhematol.2018.08.001
   PubMed Web of Science ®Google Scholar
• Agrawal-Singh S, Isken F, Agelopoulos K, et al. Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood. 2012;119(10):2346–2357. doi:10.1182/blood-2011-06-358705
   PubMed Web of Science ®Google Scholar
• Sauer T, Arteaga MF, Isken F, et al. MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML. Exp Hematol. 2015;43(9):794–802.e4. doi:10.1016/j.exphem.2015.05.010
   PubMed Web of Science ®Google Scholar
• Göttlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20(24):6969–6978. doi:10.1093/emboj/20.24.6969
   PubMed Web of Science ®Google Scholar
• Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1(3):194–202. doi:10.1038/35106079
   PubMed Web of Science ®Google Scholar
• Ungerstedt JS. Epigenetic modifiers in myeloid malignancies: the role of histone deacetylase inhibitors. Int J Mol Sci. 2018;19(10):3091. doi:10.3390/ijms19103091
   PubMed Web of Science ®Google Scholar
• Wang T, Xu H. Development of realgar nanotherapeutics for cancer treatments. In: Xu H, Gu N, editors. Nanotechnology in Regenerative Medicine and Drug Delivery Therapy. Springer Singapore; 2020:421–454.
   Google Scholar
• Ma Q, Wang C, Li X, et al. Fabrication of water-soluble polymer-encapsulated As4S4 to increase oral bioavailability and chemotherapeutic efficacy in AML mice. Sci Rep. 2016;6(1):29348. doi:10.1038/srep29348
   PubMed Web of Science ®Google Scholar
• Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood. 2002;99(9):3136–3143. doi:10.1182/blood.V99.9.3136
   PubMed Web of Science ®Google Scholar
• Zhu HH, Huang XJ, Arsenic O. Retinoic acid for non-high-risk acute promyelocytic leukemia. New Engl J Med. 2014;371(23):2239–2241. doi:10.1056/NEJMc1412035
   PubMed Web of Science ®Google Scholar
• Zhu HH, Liu YR, Jia JS, Qin YZ, Zhao XS, Lai YY. Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia. Blood. 2018;131(26):2987–2989. doi:10.1182/blood-2018-02-834051
   PubMed Web of Science ®Google Scholar
• Zhu HH, Wu DP, Du X, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised Phase 3 trial. Lancet Oncol. 2018;19(7):871–879. doi:10.1016/S1470-2045(18)30295-X
   PubMed Web of Science ®Google Scholar
• Wang T, Wen T, Li HM, et al. Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL. Int J Nanomed. 2019;14:5581–5594. doi:10.2147/Ijn.S207298
   PubMed Web of Science ®Google Scholar
• Jia M, Wang T, Xu S, et al. Arsenic sulfide nanoformulation induces megakaryocytic differentiation through histone deacetylase inhibition. Adv Ther. 2019;3(5):1900151.
   Web of Science ®Google Scholar
• Meng J, Ge Y, Xing H, et al. Synthetic CXCR4 antagonistic peptide assembling with nanoscaled micelles combat acute myeloid leukemia. Small. 2020;16(31):e2001890. doi:10.1002/smll.202001890
   PubMed Web of Science ®Google Scholar
• Larizza L, Magnani I, Beghini A. The Kasumi-1 cell line: a t (8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma. 2005;46(2):247–255. doi:10.1080/10428190400007565
   PubMed Web of Science ®Google Scholar
• Yan D, Wei H, Lai X, et al. Co-delivery of homoharringtonine and doxorubicin boosts therapeutic efficacy of refractory acute myeloid leukemia. J Control Release. 2020;327:766–778. doi:10.1016/j.jconrel.2020.09.031
   PubMed Web of Science ®Google Scholar
• Altucci L, Rossin A, Hirsch O, et al. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res. 2005;65(19):8754–8765. doi:10.1158/0008-5472.CAN-04-3569
   PubMed Web of Science ®Google Scholar
• Martin SJ, Bradley JG, Cotter TG. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol. 1990;79(3):448–453. doi:10.1111/j.1365-2249.1990.tb08110.x
   PubMed Web of Science ®Google Scholar
• Anastas JN, Zee BM, Kalin JH, et al. Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG. Cancer Cell. 2019;36(5):528–544.e10. doi:10.1016/j.ccell.2019.09.005
   PubMed Web of Science ®Google Scholar
• Keeshan K, Santilli G, Corradini F, Perrotti D, Calabretta B. Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation. Blood. 2003;102(4):1267–1275. doi:10.1182/blood-2003-02-0477
   PubMed Web of Science ®Google Scholar
• Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science. 1994;265(5178):1573–1577. doi:10.1126/science.8079170
   PubMed Web of Science ®Google Scholar
• Cantor AB, Orkin SH. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene. 2002;21(21):3368–3376. doi:10.1038/sj.onc.1205326
   PubMed Web of Science ®Google Scholar
• Shin E, Jeong JG, Chung H, et al. The Gata1(low) murine megakaryocyte-erythroid progenitor cells expand robustly and alter differentiation potential. Biochem Biophys Res Commun. 2020;528(1):46–53. doi:10.1016/j.bbrc.2020.04.143
   PubMed Web of Science ®Google Scholar
• Ram R, Amit O, Zuckerman T, et al. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study. Ann Hematol. 2019;98(8):1927–1932. doi:10.1007/s00277-019-03719-6
   PubMed Web of Science ®Google Scholar
• Molica M, Breccia M, Foa R, Jabbour E, Kadia TM. Maintenance therapy in AML: the past, the present and the future. Am J Hematol. 2019;94(11):1254–1265. doi:10.1002/ajh.25620
   PubMed Web of Science ®Google Scholar
• Short NJ, Konopleva M, Kadia TM, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10(4):506–525. doi:10.1158/2159-8290.Cd-19-1011
   PubMed Web of Science ®Google Scholar
• Wan Z, Sun R, Moharil P, et al. Research advances in nanomedicine, immunotherapy, and combination therapy for leukemia. J Leukoc Biol. 2021;109(2):425–436. doi:10.1002/jlb.5mr0620-063rr
   PubMed Web of Science ®Google Scholar
• Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N. CPX-351 (vyxeos) in AML. Leuk Lymphoma. 2020;61(2):288–297. doi:10.1080/10428194.2019.1660970
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692. doi:10.1200/jco.2017.77.6112
   PubMed Web of Science ®Google Scholar
• Xu S, Zhang M, Fang X, et al. A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia. J Hematol Oncol. 2021;14(1):193. doi:10.1186/s13045-021-01206-y
   PubMed Web of Science ®Google Scholar
• Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27(32):5459–5468. doi:10.1200/jco.2009.22.1291
   PubMed Web of Science ®Google Scholar